Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug-resistant phenotype
- PMID: 14643295
- DOI: 10.1016/s1368-7646(03)00067-0
Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug-resistant phenotype
Abstract
Histones are abundant proteins that coordinate the organization of eukaryotic nucleosomes. Post-translational modifications of histones-acetylation, phosphorylation and methylation-locally modulate the higher order nucleosome structure. Acetylation and deacetylation of histones occur at their N-terminal tails in a dynamic fashion and influence DNA accessibility to factors regulating replication, repair and transcription. Acetylation, catalyzed by histone acetyltransferases (HATs) on the epsilon-NH(2) group of lysine residues, neutralizes the positive charge and thereby triggers transcriptional activation. Deacetylation, catalyzed by histone deacetylases (HDACs) on the same lysine residues, unmasks the charge and triggers transcriptional repression. Inhibition of HDACs has thus a broad effect on chromatin architecture, and possibly on protein function, and multiple effects on cell growth. HDAC inhibitors (HDIs) are promising as single anti-cancer agents and in combination therapies. Understanding of the molecular basis for HDIs action is needed to better design the clinical antitumor treatments. The apoptotic pathways induced by HDIs are emerging and we provide an overview of the recent findings that regard apoptotic key elements. We also propose that transformed cells discern the widespread effect of HDIs on chromatin architecture as a genotoxic insult to respond to through induction of apoptosis.
Similar articles
-
HDAC Inhibitors.Methods Mol Biol. 2016;1436:281-303. doi: 10.1007/978-1-4939-3667-0_19. Methods Mol Biol. 2016. PMID: 27246222
-
Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.Adv Exp Med Biol. 2008;615:261-98. doi: 10.1007/978-1-4020-6554-5_13. Adv Exp Med Biol. 2008. PMID: 18437899 Review.
-
[Assay for inhibitory activity of histone deacetylase].Gan To Kagaku Ryoho. 2004 Apr;31(4):507-11. Gan To Kagaku Ryoho. 2004. PMID: 15114691 Japanese.
-
Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. doi: 10.2174/187152007781668698. Anticancer Agents Med Chem. 2007. PMID: 17896917 Review.
-
Histone acetylation and the cell-cycle in cancer.Front Biosci. 2001 Apr 1;6:D610-29. doi: 10.2741/1wang1. Front Biosci. 2001. PMID: 11282573 Review.
Cited by
-
Role for histone deacetylase 1 in human tumor cell proliferation.Mol Cell Biol. 2007 Jul;27(13):4784-95. doi: 10.1128/MCB.00494-07. Epub 2007 Apr 30. Mol Cell Biol. 2007. PMID: 17470557 Free PMC article.
-
DNA and the chromosome - varied _targets for chemotherapy.Cell Chromosome. 2004 May 24;3(1):2. doi: 10.1186/1475-9268-3-2. Cell Chromosome. 2004. PMID: 15157277 Free PMC article.
-
Dephosphorylation and caspase processing generate distinct nuclear pools of histone deacetylase 4.Mol Cell Biol. 2007 Oct;27(19):6718-32. doi: 10.1128/MCB.00853-07. Epub 2007 Jul 16. Mol Cell Biol. 2007. PMID: 17636017 Free PMC article.
-
PP2A regulates HDAC4 nuclear import.Mol Biol Cell. 2008 Feb;19(2):655-67. doi: 10.1091/mbc.e07-06-0623. Epub 2007 Nov 28. Mol Biol Cell. 2008. PMID: 18045992 Free PMC article.
-
Selective class IIa HDAC inhibitors: myth or reality.Cell Mol Life Sci. 2015 Jan;72(1):73-86. doi: 10.1007/s00018-014-1727-8. Epub 2014 Sep 5. Cell Mol Life Sci. 2015. PMID: 25189628 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources